Concarlo Holdings LLC

MILAN--(BUSINESS WIRE)-- Sibylla Biotech today announces the appointment of Dominique Bridon, Ph.D., as Executive Chairman of its Board of Directors. Dr. Bridon brings more than 30 years of experience in operations as well as research and development in the pharmaceutical and biotechnology sectors. As an expert in implementing AI-based technologies for drug development and with a broad knowledge base in precision oncology, Dr. Bridon has successfully led drug discovery efforts from conception to clinical development. Joining Sibylla, Dr. Bridon will contribute his expertise and lead the Board as Sibylla expands its proprietary pipeline of innovative protein degraders. “Dominique’s background in advancing new therapeutics, his proven track record as a successful biotech entrepreneur and his passion for science that is a great fit for Sibylla’s culture will be highly valuable as we enter the next stages of our corporate growth,” commented Lidia Pieri, Co-Founder and Chief Executive Officer of Sibylla Biotech. “We are leveraging our protein folding simulation platform to build out our pipeline starting with our lead candidate designed to degrade Cyclin D1, a protein that is amplified and overexpressed in a range of cancers but remains elusive to drug targeting efforts. During this period of progressive expansion in our preclinical activities, Dominique's engagement will be instrumental.” “Sibylla Biotech’s cutting-edge PPI-FIT technology has the potential to address previously undruggable targets across many indications and redefine the protein degradation landscape,” said Dr. Dominique Bridon. “I look forward to working with the team and the Board to continue advancing Sibylla’s highly-differentiated approach while driving the further development of its lead candidate in oncology.” Dr. Dominique Bridon has served as CEO of Diaccurate SAS, a clinical-stage biopharmaceutical company developing precision oncology therapies, since 2020. Prior to this, Dr. Bridon held a range of senior positions at various pharmaceutical and biotechnology companies, including Senior Vice President and acting CSO, Discovery and Innovation at Ipsen, a leader in peptide and protein therapeutics. Dr. Bridon is the scientific co-founder of several biotechnology companies and is an inventor and co-inventor of more than 50 patents and patent applications. He is also a member of the Scientific Boards of Jalon Therapeutics, Concarlo Therapeutics, and EpiVax Therapeutics. Dr. Bridon holds a Ph.D. in Organic Chemistry from the University of Paris XI and completed a post-doctoral research position at the University of California, Berkeley. He obtained an M.S. in Chemical Engineering from the École Nationale Supérieure de Chimie and an M.S. in Polymer Sciences from the University of Clermont-Ferrand. About Sibylla Biotech Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein. Through its protein folding simulation technology platform, Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. For further information: View source version on businesswire.com: Contacts Sibylla Biotech Lidia Pieri +39 347 6499534 lidia.pieri@sibyllabiotech.it Trophic Communications Valeria Fisher or Dr. Alison Opalko +49 175 80 41 816 or +49 151 54041130 sibylla@trophic.eu Source: Sibylla Biotech View this news release online at:

Nearly $5 million invested in eight new promising Mid-Atlantic life sciences companies PHILADELPHIA, Nov. 9, 2022 /PRNewswire/ -- BioAdvance, a leading venture investor in therapeutics, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region, today announced a record-breaking year of investing with more than $4.7 million in eight new and several existing portfolio companies in 2022. During this highly active year, BioAdvance's investments in the eight new companies is the highest amount in 10 years, resulting from a revamped investment strategy that includes very early-stage innovators from a broad range of life sciences segments including digital health and cell therapy. "For more 20 years, BioAdvance has played an important role in the development of the thriving Mid-Atlantic biotechnology ecosystem," said BioAdvance Managing Director and CEO Dr. Shahram Hejazi. "We will continue to expand our impact by supporting promising early-stage technologies and entrepreneurs with both funding and expertise to help grow their businesses and in turn impact human health." BioAdvance invests at two stages of a company's lifecycle. With its renewed "pilot" strategy, up to $200,000 is invested in companies that seek to accomplish one or more critical milestones that enable a subsequent, larger institutional fundraising round. Standard BioAdvance venture investments in Seed and Series A rounds are substantially larger at up to $1.5 million initially and up to $5 million in the lifetime of companies and often made as part of a syndicate of investors. 2022 Investments FY 2022 new investments are as follows. Concarlo Therapeutics develops drugs that modulate an important pathway in cancer cell growth more effectively than current options. Eliksa Therapeutics aims to be the major supplier of FDA-approved amniotic fluid and membrane products for treatment of a variety of inflammatory conditions. KaloCyte develops a red blood cell substitute for treatment of acute blood loss. Kayothera develops cancer treatments aimed at a novel pathway that impacts cancer cell growth and metastasis. Phrase Health is a digital health company that provides tools to health systems to analyze and govern their clinical decision support. Senzo develops a handheld diagnostic device for COVID and other infectious diseases with the ease of use and low cost of current products but much higher sensitivity and specificity. SIRPant Immunotherapeutics develops cancer treatments using conditioned macrophages with enhanced immunotherapeutic activity. Vesteck is a medical device company developing novel aortic endograft anchors that improve outcomes and are easier to deploy. BioAdvance also made several follow-on investments in existing portfolio companies, including ENB Therapeutics , RightAir, Ossianix and Venatorx Pharmaceuticals. About BioAdvance BioAdvance is a $80-million early-stage life sciences fund with a focus in the mid-Atlantic region, investing in companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed more than $55 million in funding to approximately 100 organizations developing more than 160 products in the diagnostics, therapeutic, medtech, research tools and digital health sectors. BioAdvance portfolio companies have leveraged $3.8 billion in subsequent capital, including proceeds from acquisitions. Eleven products have received FDA approval. For more information, please visit . Contact: Marnie McCoy Program Director [email protected] SOURCE BioAdvance

Senior Leader Brings Deep Biotech and Pharmaceutical Industry Experience BROOKLYN, N.Y., July 27, 2022 /PRNewswire/ -- Concarlo Therapeutics ("Concarlo"), a pre-clinical biotech company whose mission is to dramatically improve outcomes for patients with drug resistant cancers by creating transformative therapies that control the p27 target, has hired Vadim Shepel as Chief Business & Operating Officer. In this newly created role, Mr. Shepel will lead all aspects of Concarlo's business strategy, including business development, finances, operations and investor relations. He joins Concarlo from BeiGene where he was the Senior Director of New Market Development. Previously he spent five years at Pfizer where he was the Director of Strategy and Consulting in the Vaccines and Hospital Business Units. Mr. Shepel reports to Dr. Stacy Blain, Concarlo's Co-Founder and Chief Scientific Officer. Building a high performing team that can translate scientific innovation into commercially viable therapeutics is key to saving more lives among those who are diagnosed with cancer. Advances in precision oncology have made the outlook for people with cancer more hopeful than ever. Through molecular profiling and genetic sequencing, medical professionals are now matching patients with the treatments that stand the highest likelihood of success. Yet, despite this great progress, more than 600,000 patients continue dying each year in the U.S. from cancer. "Vadim is a highly talented executive who will help drive Concarlo's business strategy and operations and he will play a critical role in the development of our business," said Dr. Blain. "He joins our world-class leadership team which will enable us to achieve our vision to create a world of possibility, hope and time by making cancer a treatable, manageable and survivable condition." "I believe that addressing drug resistance is one of the most pressing issues in cancer care and the next paradigm shift in oncology. I am thrilled to join Concarlo's team, work alongside renowned experts from across scientific disciplines, and bring the company's transformative therapy to patients," said Mr. Shepel. Concarlo has assembled an experienced team of purpose-driven leaders in science and business, including: Dr. Stacy Blain, Co-Founder and Chief Scientific Officer Jason Mraz, President Dr. Krishna Allamneni, Chief Development Officer Sean Larkin, Head of Operations The company has also created a Business Advisory Board comprised of a number of highly regarded leaders, including: Jay Campbell, Managing Director, Clinical Accelerator and Venture Fund at Cancer Research Institute (CRI) Dr. Alicia Chung, Strategy & Business Development at Bionaut Labs Michael Harrington, Former Senior Vice President and General Counsel at Eli Lilly and Company Arthur Klausner, President & CEO, Goldilocks Therapeutics Michael P. Miller, Former EVP Commercial, Jazz Pharmaceuticals Professional Biography of Mr. Shepel: Vadim Shepel joined Concarlo Therapeutics in July 2022 as Chief Business & Operating Officer, reporting to Dr. Stacy Blain, the company's Co-Founder and Chief Scientific Officer. Previously he was Senior Director of New Market Development at BeiGene, a global science-driven biotechnology company. Prior to that Mr. Shepel spent five years at Pfizer, most recently as Director of Strategy and Consulting in the Vaccines and Hospital Business Units. Earlier in his career Mr. Shepel served in a number of roles with the Clinton Health Access Initiative where he worked on expanding access to HIV and Malaria medicines across Sub-Saharan Africa through partnerships with local governments, pharmaceutical companies and multilateral organizations such as the WHO, United Nations and the Bill & Melinda Gates Foundation. He began his career in the financial services industry, with investment roles at First New York Securities and BNP Paribas Fortis. Mr. Shepel earned his BA in Economics with a Minor in Computer Science from New York University. About Concarlo: Concarlo ( ) is a preclinical biotech company whose mission is to transform the treatment of all drug-resistant cancers by leveraging the unique characteristics of the p27 target. The company is female-founded and led, with a team of world-class scientists, drug developers, and scientific advisors. Despite many important advances in precision oncology, drug-resistance remains one of the major reasons for the more than 600,000 cancer deaths in America each year. Concarlo is harnessing decades of research and experience to clean up what precision oncology leaves behind by targeting a unique cellular pathway. We are driven by our vision of creating a world of possibility and time, where cancer is a treatable, manageable and survivable condition.